Orbital Atherectomy

Continuing Education Activity

Orbital atherectomy (OA) is an adjunctive therapy used for lesion preparation of calcified plaque with percutaneous coronary intervention (PCI) and peripheral percutaneous endovascular interventions. The goal of lesion preparation with OA is to modify calcified plaque, changing lesion compliance to allow adequate balloon and stent expansion in segments with heavily calcified lesions. This activity highlights the role of the interprofessional team in evaluating and improving care for patients undergoing this procedure.

Objectives:

• Describe the pathophysiology of coronary artery calcification.
• Outline the indications for orbital atherectomy.
• Identify the common complications of orbital atherectomy
• Describe the procedural technique for performing orbital atherectomy.

Introduction

Orbital atherectomy (OA) is an adjunctive therapy used for lesion preparation of calcified plaque before percutaneous coronary intervention (PCI) and peripheral percutaneous endovascular interventions. The goal of lesion preparation with OA is to modify calcified plaque, which changes the lesion compliance and allows for the adequate balloon and stent expansion in segments with heavily calcified lesions.

Coronary artery disease (CAD) has a significant impact on overall health and continues to grow in prevalence in the United States. Data from the American Heart Association states that greater than 15.5 million people over age 20 have significant CAD.[1] The deaths due to cardiovascular disease have also steadily increased since 1990 [2], with nearly 650,000 deaths due to cardiovascular disease in 2019.[1] In patients with advanced CAD, coronary artery calcification (CAC) is associated with increased atherosclerosis and potential future cardiac events.[3] 

CAC is believed to be both gender and age-dependent. The prevalence of CAC in individuals over age 70 has been estimated to be greater than 90% in men and 67% in women.[4] CAC is better detected using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) compared to coronary angiography. A previous study in patients with known CAD demonstrated that coronary angiography could detect coronary calcium in 38% of lesions versus 73% utilizing IVUS.[5] As intravascular imaging modalities are underutilized, CAC is likely underestimated in the general population.[3]

As CAD prevalence increases, the incidence of CAC follows a similar trend. Previous studies have shown that those patients with severe CAC have more complex and worse outcomes when undergoing percutaneous intervention (PCI) than patients with low CAC.[6][7] The importance of recognizing CAC is rooted in previous studies demonstrating technically more challenging cases of PCI, as well as worse outcomes. Two different meta-analyses have revealed that severe coronary calcium is associated with less complete revascularization, increased mortality, increased rate of myocardial infarction (MI), and increased rate of coronary revascularization.[8][9] The noted worse outcomes in patients with severe coronary calcium are multifactorial but are likely strongly associated with poor balloon expansion resulting in incomplete stent expansion and coronary calcium damaging stent polymer coating, decreasing efficacy.[10][11][12] 

To help decrease complication rates and improve stent deployment in patients with severe CAC, utilization of OA can be of significant benefit for vessel preparation and stent placement. In this manuscript, we provide a review of OA and the available devices, techniques, indications, complications, contraindications, and clinical trial outcomes based on the most recent data.

Anatomy and Physiology

Calcified coronary plaques pose numerous challenges to successful PCI, often prohibiting stent delivery or inhibiting complete stent expansion.[13][14] PCI of calcified lesions in which there is incomplete expansion is associated with worse long-term outcomes.[6][15][16] CAC is known to negatively affect vascular anatomy, resulting in decreased vascular compliance, decreased/atypical vasomotor responses to stimuli, and impaired oxygen delivery to the myocardium.[17] 

Vascular calcification is a complex and dynamic process for which the pathophysiology is not completely understood. Previous theories have been based on calcium/phosphate imbalance, circulating nucleation complexes, apoptotic bodies, and bone formation, while more recent studies have proposed microRNAs may play a role as regulators of vascular smooth muscle cells.[4][18] 

Though the exact pathophysiology of CAC remains unknown, certain risk factors have been associated with more severe and advanced CAC. Coronary calcification can occur in both the tunica intima and tunica media, but calcification of the media is believed to be more associated with cardiovascular events.[4][19] 

The most common risk factors for CAC include smoking/tobacco use, obesity, hypertension, diabetes mellitus, advanced age, chronic kidney disease, male gender, and Caucasian race.[1][3][18][10] These risk factors for CAC are continuing to rise in prevalence in the United States based on the Heart Disease and Stroke Statistics-2019 Update.[1]

Indications

For coronary arteries, orbital atherectomy (OA) is indicated to facilitate stent delivery in patients with known severely calcified coronary artery lesions who are candidates for percutaneous transluminal coronary angioplasty or stenting. The Orbital Atherectomy System has the Food and Drug Administration (FDA) approval to treat severely calcified coronary artery lesions.[3] Situations in which to consider the use or OA is dependent on the thickness and severity of calcification. Previous studies have suggested that lesions with calcium thickness < 0.24 mm are likely to fracture and can be treated with balloon angioplasty before stent placement.[20] Similarly, lesions with a calcium score of 4 or more are at increased risk of the stent under expansion.[21] In either case of increased calcium thickness or score, atherectomy before stent placement may be beneficial for successful stent placement.[22]

Though there are no further manufacturer indications, the clinical application may be extended to other situations given the crown size and the ability to adjust ablation diameter. Potential situations to utilize OA include severely calcified lesions in a patient with multi-vessel disease, lesion preparation for bioresorbable scaffold placement, unprotected left main disease, ostial lesions, and chronic total occlusions.[23] Further trials and data will be necessary to determine further clinical indications and situations for which OA will be an indicated therapy.

Contraindications

Orbital atherectomy (OA) is contraindicated in the following conditions:

1. Unable to pass the guidewire  across a lesion
2. The lesion is within a graft or stent
3. The patient is not a candidate for atherectomy, coronary angioplasty, or bypass surgery
4. The patient has evidence of thrombus on angiography
5. The patient has a multi-vessel disease with only one open coronary vessel
6. There is evidence of coronary dissection on the angiogram
7. The patient is pregnant
8. The patient is a child[3][24] 

Other warnings and precautions for consideration before utilizing OA include:

1. Very tortuous vessels which are at increased risk for vessel damage
2. Treating lesions in the right coronary or left circumflex regions as there is an increased risk for heart block and need for temporary pacing
3. On-site and available cardiothoracic surgery staff if needed
4. Patients with heart failure and reduced ejection fraction less than 25%[3]

Equipment

The orbital atherectomy system (OAS) comprises the following components:  coronary orbital atherectomy device (OAD), orbital atherectomy system pump, coronary guidewire, and lubricant. The OAD consists of a sheath-covered drive shaft, a 1.25/1.50 mm crown that slides over the VIPERWIRE coronary guidewire, a crown advancer knob, and a saline tubing connection to the OAS pump. A tableside motor handle controls crown rotation speed, guides crown advancement, and contains the guidewire brake leaver.[3]

A minimum size 6 french guide or larger is needed for the use of the OAS. The lubricant combined with saline is attached to the pump and must always be utilized during OA to help reduce the risk of thermal injury and potential heart block.[24] The saline flow rate is controlled by the pump and is approximately 18 ml/min, but can be increased throughout the procedure as needed.[3] The device setup is efficient and can be assembled in minutes by an experienced operator.[25]

Personnel

A cardiac team made up of interventional cardiologists, cath lab technicians, nurse practitioners/provider assistants, and cardiac catheterization laboratory are necessary to allow for the best possible outcomes for patients undergoing orbital atherectomy (OA). Cardiac catheterization technicians and nurses need to be available for patient check-in and laboratory testing, intra-procedure vitals monitoring, and post-procedure to evaluate the patient for any new symptoms, evidence of hemodynamic instability, or procedural complications. 

During OA, the procedure is performed by an interventional cardiologist using a single-operator technique.[25] Before using the coronary orbital atherectomy system (OAS) in the United States, the user must complete a training and certification program. Certification requirements include the completion of online training modules as well as a minimum of six proctored cases. Depending on experience, a preceptorship course may be required.[23]

Preparation

A thorough review of the patient's past medical history, surgical history, medications, and allergies is imperative to optimize outcomes. A critical review of previous cardiac imaging and tests, including electrocardiograms, echocardiograms, stress tests, and past angiograms, helps to delineate coronary anatomy in preparation for the planned intervention. Understanding any previous interventions is essential for planning before the procedure. Based on patient anatomy and the proceduralist's personal preference, an arterial access site should be chosen before starting the case. All personals who will be in contact with the patient must scrub using sterile technique. After necessary members have been donned in sterile gowns and gloves, and a time-out has been conducted, the orbital atherectomy (OA) procedure can begin.

Technique or Treatment

Before starting, the procedural team should gather all necessary equipment (coronary orbital atherectomy system, guide catheter, IV pole, normal saline, and fluoroscopy imaging equipment), set up the OAS pump to an IV pole with the saline level sensor connected, and a stiff coronary guidewire prepped for insertion.

With all equipment assembled and personal in place, the atherectomy procedure can be initiated. Start with obtaining arterial vascular access using a 6 Fr sheath or larger using the provider's preferred approach. Access the lesion with a guide catheter, and use angiography, IVUS, or OCT to localize and evaluate the target lesion. Once located, cross the lesion with the coronary guidewire. Prepare the lubricant, connect the OAD to the OAS, and prime the pump. Before inserting the OAD into the vessel, perform testing to ensure appropriate crown advancement via advancer knob and crown rotation using the on/off button. Verify the flow of saline with crown rotation. Ensure the brake lever is open, and advance the OAD drive shaft over the guidewire. Using fluoroscopy, advance the crown to approximately 10 mm proximal to the target lesion. Verify the OAD distal tip is beyond the lesion. Press down on the brake lever to engage the brake and press the on/off button to activate crown rotation at low speed (80,000 rpm), which can be verified via the LED light on the OAD.

Advance the crown to begin atherectomy via the advancer knob no faster than 1 mm per second. Once the crown is orbiting, maintaining continuous movement is important as remaining in one location can cause damage to the coronary vessel. Under fluoroscopy, ensure the crown and crown advancer knob move in a 1 to 1 fashion. Perform a series of intermittent treatment intervals back and forth across the lesion, followed subsequently by a rest period with the crown on the proximal side of the lesion.

Each rest period should be of equal length or greater than the treatment time. A maximum recommended treatment interval is 30 seconds (the OAS pump will emit a beep after 25 seconds of treatment time). If the desired result is not observed at low speed, consider high speed (120,000 rpm) if no tortuosity is identified and vessel size is adequate.[3][22][23]

Due to wear that can result in the equipment, the maximum treatment time per OAD is 5 minutes. The OAD does not keep track of treatment time; thus, this should be timed by a team member during each procedure. Lastly, a replacement bag of saline and lubricant should be readily available if needed during complex procedures. Following the completion of OA to the target lesion, lock the control, and then the OAD can be safely removed from the vessel. Evaluate the lesion with a balloon for complete expansion. If balloon under-expansion is noted, further runs of OA may be needed for particular lesion segments. Alternatively, intravascular imaging can be used to assess the treatment of the target lesion before stent placement.[22]

Complications

Orbital atherectomy (OA) has been demonstrated to be a safe and effective device in both clinical studies and all-comer real-world registries.[26][27][28][29] Complications have been reported to be low in high-risk patient cohorts and lesion sub-types including females, diabetics, elderly, and patients with chronic kidney disease, low ejection fraction, previous coronary artery bypass grafts, subtotal occlusions, left main coronary artery lesions, aorto-ostial lesions, bifurcations, and small coronary vessels.[30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47]

The most commonly reported complications associated with orbital atherectomy include dissections, slow or no-reflow, and perforations. In the ORBIT I trial involving 50 patients, there were six coronary dissections without clinical sequelae and only one perforation. There was no noted incidence of slow flow or distal emboli.[48] Similar results were noted in the much larger ORBIT II with 443 patients enrolled, with rates of dissection, perforation, and no flow being 3.4%, 1.8%, and 0%, respectively.[49] 

A transient heart block is uncommon with orbital atherectomy, but bradycardia has been observed. In a 2017 study by Lee et al. involving 50 patients, 4% experienced bradycardia, none of which required pacemaker implantation.[50][51] 

Rare complications have been reported and include pseudoaneurysm and dislodged microtip.[52][53][54][55] A more recent review using the MAUDE database revealed 317 submitted cases in which there was device failure. The most common device malfunctions included detachment/separation of pieces and device structural damage. Structural damage was reported involving the following components: crown, body, and tip of guidewire tip, driveshaft tip, and driveshaft body.[56]

Clinical Significance

The utilization of atherectomy has been increasing but remains low compared with the prevalence of heavily calcified lesions.[57] The first study in humans was ORBIT I, a nonrandomized study with 50 patients that evaluated the safety and feasibility of orbital atherectomy (OA) to treat de novo heavily calcified lesions.[48] In this study, procedural success was 94%.[22] This was followed by the ORBIT II trial, a multicenter, prospective, open-label trial with 443 patients. The study lacked a control arm as no other device had FDA approval for lesion preparation for comparison. ORBIT II's primary endpoint was measured as a 30-day major adverse cardiovascular event (MACE). Following OA, 89.6% had freedom from 30-day MACE (95% CI 86.7%-92.55%). The in-hospital MACE, 1-year MACE, and 3-year MACE were 9.8%, 16.4%, and 23.5%, respectively.[48][58][26] The MACE results in ORBIT II were lower at three years compared to two years in the ROTATAXUS study, in which patients underwent rotational atherectomy (RA).[26][59] Given the results of ORBIT II, OA gained FDA approval in 2013.

Despite the success seen in the ORBIT II trial, multiple high-risk groups were not included: patients with unprotected left main disease and those with ejection fraction < 25%. These high-risk individuals were included in a 2018 study, including all patients undergoing OA at three separate institutions. One year following OA, 87.3% had not experienced a MACE or cerebrovascular event, demonstrating that OA is an option for treatment in patients with severely calcified and complex coronary anatomy.[28]

Since the advent of OA, there have been questions on the economic value of atherectomy and preparation of calcified lesions before PCI. This was addressed by performing a cost savings analysis using the ORBIT II data and comparing it with medicare provider analysis and review (MedPar) data. In the study, the first significant finding was the decrease in the index procedure cost of $3590 per patient. This was considered to be due to decreased average length of stay for patients in ORBIT II (1.8 days vs. 4.24 days). The second major finding was a decreased procedure-related readmission rate for coronary artery bypass surgery at one month in ORBIT II compared with MedPar data, resulting in a decreased cost of $704. In total, the combined savings per patient was $4294 in patients undergoing OA.[60][61][24]

Given the outcomes of the ORBIT II and real word multicenter trials, larger trials are needed to evaluate the utility of OA in patients with severe coronary calcification. This is being addressed in the ongoing evaluation of treatment strategies for severe calcific coronary arteries: orbital atherectomy vs. conventional angioplasty technique, before implantation of drug-eluting stents: ECLIPSE trial. This is a multicenter, randomized control since 2017, with an estimated end date in February 2022. Primary endpoints include the final minimum stent area after the procedure via OCT and target vessel failure.

Enhancing Healthcare Team Outcomes

Undergoing cardiac catheterization is a common yet complicated procedure in which complications can be life-threatening. As orbital atherectomy (OA) is still a relatively new procedure, no guidelines are written that incorporate its use by the major governing bodies in cardiology. To help optimize outcomes, especially when implementing a new procedure, utilizing an interprofessional healthcare team is paramount. While the interventional cardiologist is significantly involved when the patient is in the catheterization laboratory, an entire team is necessary from beginning to end to help minimize poor outcomes.

Based on the 2016 SCAI expert consensus statement for best practices in the cardiac catheterization laboratory (CCL), a multidisciplinary team made up a cardiologist, cardiac trainees, cardiothoracic surgeons, an anesthesia provider for cases involving more than moderate sedation, provider assistants/nurse practitioners, registered nurses, and catheterization laboratory technicians are required to help ensure the success of any procedure.[62] It is recommended that 1 or 2 CCL staff are always present at tableside, with at least two additional CCL staff available for monitoring, recording, providing moderate sedation, and circulating.[Level 5]

With further complexities in patient care, incorporating medical teams from multiple disciplines will be essential to ensure the best care possible and improve outcomes for patients. The Heart Team has well exemplified this, first described by Holmes et al., and has now been included in the European Society of Cardiology and American College of Cardiology/American Heart Association guidelines.[63][64] [Level 5] With this multidisciplinary approach being a class I indication, it has been proven safe and efficacious when initiated at various institutions.[65][66] [Level 1]

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O'Flaherty M, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS., American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019 Mar 05;139(10):e56-e528. [PubMed: 30700139]

2.

Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016 Jul;4(13):256. [PMC free article: PMC4958723] [PubMed: 27500157]

3.

Shlofmitz E, Martinsen BJ, Lee M, Rao SV, Généreux P, Higgins J, Chambers JW, Kirtane AJ, Brilakis ES, Kandzari DE, Sharma SK, Shlofmitz R. Orbital atherectomy for the treatment of severely calcified coronary lesions: evidence, technique, and best practices. Expert Rev Med Devices. 2017 Nov;14(11):867-879. [PubMed: 28945162]

4.

Liu W, Zhang Y, Yu CM, Ji QW, Cai M, Zhao YX, Zhou YJ. Current understanding of coronary artery calcification. J Geriatr Cardiol. 2015 Nov;12(6):668-75. [PMC free article: PMC4712374] [PubMed: 26788045]

5.

Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Chuang YC, Ditrano CJ, Leon MB. Patterns of calcification in coronary artery disease. A statistical analysis of intravascular ultrasound and coronary angiography in 1155 lesions. Circulation. 1995 Apr 01;91(7):1959-65. [PubMed: 7895353]

6.

Généreux P, Madhavan MV, Mintz GS, Maehara A, Palmerini T, Lasalle L, Xu K, McAndrew T, Kirtane A, Lansky AJ, Brener SJ, Mehran R, Stone GW. Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) TRIALS. J Am Coll Cardiol. 2014 May 13;63(18):1845-54. [PubMed: 24561145]

7.

Madhavan MV, Tarigopula M, Mintz GS, Maehara A, Stone GW, Généreux P. Coronary artery calcification: pathogenesis and prognostic implications. J Am Coll Cardiol. 2014 May 06;63(17):1703-14. [PubMed: 24530667]

8.

Zhang YJ, Zhu LL, Bourantas CV, Iqbal J, Dong SJ, Campos CM, Li MH, Ye F, Tian NL, Garcia-Garcia HM, Serruys PW, Chen SL. Impact of everolimus versus other rapamycin derivative-eluting stents on clinical outcomes in patients with coronary artery disease: a meta-analysis of 16 randomized trials. J Cardiol. 2014 Sep;64(3):185-93. [PubMed: 24560821]

9.

Bourantas CV, Zhang YJ, Garg S, Iqbal J, Valgimigli M, Windecker S, Mohr FW, Silber S, Vries Td, Onuma Y, Garcia-Garcia HM, Morel MA, Serruys PW. Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. Heart. 2014 Aug;100(15):1158-64. [PubMed: 24846971]

10.

Lee MS, Shah N. The Impact and Pathophysiologic Consequences of Coronary Artery Calcium Deposition in Percutaneous Coronary Interventions. J Invasive Cardiol. 2016 Apr;28(4):160-7. [PubMed: 26301561]

11.

Nakano M, Otsuka F, Yahagi K, Sakakura K, Kutys R, Ladich ER, Finn AV, Kolodgie FD, Virmani R. Human autopsy study of drug-eluting stents restenosis: histomorphological predictors and neointimal characteristics. Eur Heart J. 2013 Nov;34(42):3304-13. [PMC free article: PMC3819590] [PubMed: 23824827]

12.

Nishida K, Kimura T, Kawai K, Miyano I, Nakaoka Y, Yamamoto S, Kaname N, Seki S, Kubokawa S, Fukatani M, Hamashige N, Morimoto T, Mitsudo K., j-Cypher Registry Investigators. Comparison of outcomes using the sirolimus-eluting stent in calcified versus non-calcified native coronary lesions in patients on- versus not on-chronic hemodialysis (from the j-Cypher registry). Am J Cardiol. 2013 Sep 01;112(5):647-55. [PubMed: 23707041]

13.

Shlofmitz E, Zafar N, Khalid N. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 31, 2023. Calcified Plaque. [PubMed: 30969685]

14.

Shlofmitz E, Khalid N, Hashim H. Expanding the Treatment of Calcified Lesions. Cardiovasc Revasc Med. 2019 Nov;20(11):1032. [PubMed: 31080167]

15.

Redfors B, Maehara A, Witzenbichler B, Weisz G, Stuckey TD, Henry TD, McAndrew T, Mehran R, Kirtane AJ, Stone GW, Généreux P. Outcomes After Successful Percutaneous Coronary Intervention of Calcified Lesions Using Rotational Atherectomy, Cutting-Balloon Angioplasty, or Balloon-Only Angioplasty Before Drug-Eluting Stent Implantation. J Invasive Cardiol. 2017 Nov;29(11):378-386. [PubMed: 28623669]

16.

Généreux P, Madhavan MV, Mintz GS, Maehara A, Kirtane AJ, Palmerini T, Tarigopula M, McAndrew T, Lansky AJ, Mehran R, Brener SJ, Stone GW. Relation between coronary calcium and major bleeding after percutaneous coronary intervention in acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy and Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trials). Am J Cardiol. 2014 Mar 15;113(6):930-5. [PubMed: 24440325]

17.

Wang L, Jerosch-Herold M, Jacobs DR, Shahar E, Detrano R, Folsom AR., MESA Study Investigators. Coronary artery calcification and myocardial perfusion in asymptomatic adults: the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2006 Sep 05;48(5):1018-26. [PMC free article: PMC1853335] [PubMed: 16949496]

18.

Leopold JA. MicroRNAs Regulate Vascular Medial Calcification. Cells. 2014 Oct 14;3(4):963-80. [PMC free article: PMC4276909] [PubMed: 25317928]

19.

Kalra SS, Shanahan CM. Vascular calcification and hypertension: cause and effect. Ann Med. 2012 Jun;44 Suppl 1:S85-92. [PubMed: 22713153]

20.

Fujino A, Mintz GS, Lee T, Hoshino M, Usui E, Kanaji Y, Murai T, Yonetsu T, Matsumura M, Ali ZA, Jeremias A, Moses JW, Shlofmitz RA, Kakuta T, Maehara A. Predictors of Calcium Fracture Derived From Balloon Angioplasty and its Effect on Stent Expansion Assessed by Optical Coherence Tomography. JACC Cardiovasc Interv. 2018 May 28;11(10):1015-1017. [PubMed: 29798768]

21.

Fujino A, Mintz GS, Matsumura M, Lee T, Kim SY, Hoshino M, Usui E, Yonetsu T, Haag ES, Shlofmitz RA, Kakuta T, Maehara A. A new optical coherence tomography-based calcium scoring system to predict stent underexpansion. EuroIntervention. 2018 Apr 06;13(18):e2182-e2189. [PubMed: 29400655]

22.

Shlofmitz E, Shlofmitz R, Lee MS. Orbital Atherectomy: A Comprehensive Review. Interv Cardiol Clin. 2019 Apr;8(2):161-171. [PubMed: 30832940]

23.

Sotomi Y, Shlofmitz RA, Colombo A, Serruys PW, Onuma Y. Patient Selection and Procedural Considerations for Coronary Orbital Atherectomy System. Interv Cardiol. 2016 May;11(1):33-38. [PMC free article: PMC5808671] [PubMed: 29588702]

24.

Chambers JW, Diage T. Evaluation of the Diamondback 360 Coronary Orbital Atherectomy System for treating de novo, severely calcified lesions. Expert Rev Med Devices. 2014 Sep;11(5):457-66. [PubMed: 24961517]

25.

Lee MS, Nguyen H, Philipson D, Shlofmitz RA. "Single-Operator" Technique for Advancing the Orbital Atherectomy Device. J Invasive Cardiol. 2017 Mar;29(3):92-95. [PubMed: 28255104]

26.

Généreux P, Lee AC, Kim CY, Lee M, Shlofmitz R, Moses JW, Stone GW, Chambers JW. Orbital Atherectomy for Treating De Novo Severely Calcified Coronary Narrowing (1-Year Results from the Pivotal ORBIT II Trial). Am J Cardiol. 2015 Jun 15;115(12):1685-90. [PubMed: 25910525]

27.

Généreux P, Bettinger N, Redfors B, Lee AC, Kim CY, Lee MS, Shlofmitz RA, Moses JW, Stone GW, Chambers JW. Two-year outcomes after treatment of severely calcified coronary lesions with the orbital atherectomy system and the impact of stent types: Insight from the ORBIT II trial. Catheter Cardiovasc Interv. 2016 Sep;88(3):369-77. [PubMed: 27084293]

28.

Lee MS, Shlofmitz E, Goldberg A, Shlofmitz R. Multicenter Registry of Real-World Patients With Severely Calcified Coronary Lesions Undergoing Orbital Atherectomy: 1-Year Outcomes. J Invasive Cardiol. 2018 Apr;30(4):121-124. [PubMed: 29610442]

29.

Lee MS, Shlofmitz E, Kaplan B, Alexandru D, Meraj P, Shlofmitz R. Real-World Multicenter Registry of Patients with Severe Coronary Artery Calcification Undergoing Orbital Atherectomy. J Interv Cardiol. 2016 Aug;29(4):357-62. [PMC free article: PMC5096015] [PubMed: 27358246]

30.

Lee MS, Shlofmitz E, Mansourian P, Sethi S, Shlofmitz RA. Gender-Based Differences in Outcomes After Orbital Atherectomy for the Treatment of De Novo Severely Calcified Coronary Lesions. J Invasive Cardiol. 2016 Nov;28(11):440-443. [PubMed: 27801655]

31.

Janas AJ, Milewski KP, Buszman PP, Trendel W, Kolarczyk-Haczyk A, Hochuł M, Pruski M, Wojakowski W, Buszman PE, Kiesz RS. Long term outcomes in diabetic patients treated with atherectomy for peripheral artery disease. Cardiol J. 2020;27(5):600-607. [PMC free article: PMC8078980] [PubMed: 30394507]

32.

Lee MS, Martinsen BJ, Lee AC, Behrens AN, Shlofmitz RA, Kim CY, Chambers JW. Impact of diabetes mellitus on procedural and one year clinical outcomes following treatment of severely calcified coronary lesions with the orbital atherectomy system: A subanalysis of the ORBIT II study. Catheter Cardiovasc Interv. 2018 May 01;91(6):1018-1025. [PubMed: 28733974]

33.

Whitbeck MG, Dewar J, Behrens AN, Watkins J, Martinsen BJ. Acute outcomes after coronary orbital atherectomy at a single center without on-site surgical backup: An experience in diabetics versus non-diabetics. Cardiovasc Revasc Med. 2018 Sep;19(6S):12-15. [PubMed: 29804796]

34.

Lee MS, Shlofmitz E, Nguyen H, Shlofmitz RA. Outcomes in Diabetic Patients Undergoing Orbital Atherectomy System. J Interv Cardiol. 2016 Oct;29(5):491-495. [PubMed: 27489020]

35.

Lee MS, Anose BM, Martinsen BJ, Lee AC, Shlofmitz RA, Chambers JW. Orbital atherectomy treatment of severely calcified native coronary lesions in patients with prior coronary artery bypass grafting: Acute and one-year outcomes from the ORBIT II trial. Cardiovasc Revasc Med. 2018 Jul;19(5 Pt A):498-502. [PubMed: 29117920]

36.

Lee MS, Shlofmitz E, Nayeri A, Hollowed J, Shlofmitz RA. Outcomes of Patients With a History of Coronary Artery Bypass Grafting Who Underwent Orbital Atherectomy for Severe Coronary Artery Calcification. J Invasive Cardiol. 2017 Oct;29(10):359-362. [PubMed: 28974662]

37.

Lee MS, Shlofmitz E, Park KW, Goldberg A, Jeremias A, Shlofmitz R. Orbital Atherectomy of Severely Calcified Unprotected Left Main Coronary Artery Disease: One-Year Outcomes. J Invasive Cardiol. 2018 Jul;30(7):270-274. [PubMed: 29958177]

38.

Lee MS, Shlofmitz E, Shlofmitz R, Sahni S, Martinsen B, Chambers J. Outcomes After Orbital Atherectomy of Severely Calcified Left Main Lesions: Analysis of the ORBIT II Study. J Invasive Cardiol. 2016 Sep;28(9):364-9. [PubMed: 26984932]

39.

Lee MS, Shlofmitz E, Kong J, Srivastava PK, Al Yaseen S, Sosa FA, Gallant M, Shlofmitz R. Outcomes of patients with severely calcified aorto-ostial coronary lesions who underwent orbital atherectomy. J Interv Cardiol. 2018 Feb;31(1):15-20. [PubMed: 28870003]

40.

Chambers JW, Warner C, Cortez J, Behrens AN, Wrede DT, Martinsen BJ. Outcomes after Atherectomy Treatment of Severely Calcified Coronary Bifurcation Lesions: A Single Center Experience. Cardiovasc Revasc Med. 2019 Jul;20(7):569-572. [PubMed: 30201481]

41.

Lee MS, Shlofmitz RA, Shlofmitz E, Behrens AN, Revtyak G, Martinsen BJ, Chambers JW. Procedural and Long-Term Ischemic Outcomes of Tight Subtotal Occlusions Treated with Orbital Atherectomy: An ORBIT II Subanalysis. Cardiovasc Revasc Med. 2019 Jul;20(7):563-568. [PubMed: 30243964]

42.

Lee MS, Shlofmitz E, Shlofmitz R. Outcomes of Orbital Atherectomy in Severely Calcified Small (2.5 mm) Coronary Artery Vessels. J Invasive Cardiol. 2018 Aug;30(8):310-314. [PubMed: 30068786]

43.

Lee MS, Shlofmitz RA, Martinsen BJ, Sethi S, Chambers JW. Impact of age following treatment of severely calcified coronary lesions with the orbital atherectomy system: 3-year follow-up. Cardiovasc Revasc Med. 2018 Sep;19(6):655-659. [PubMed: 29452841]

44.

Shlofmitz E, Meraj P, Jauhar R, Sethi SS, Shlofmitz RA, Lee MS. Safety of orbital atherectomy in patients with left ventricular systolic dysfunction. J Interv Cardiol. 2017 Oct;30(5):415-420. [PubMed: 28722196]

45.

Lee MS, Shlofmitz E, Lluri G, Kong J, Neverova N, Shlofmitz R. Outcomes of patients with myocardial infarction who underwent orbital atherectomy for severely calcified lesions. Cardiovasc Revasc Med. 2017 Oct-Nov;18(7):497-500. [PubMed: 28529094]

46.

Doshi R, Shlofmitz E, Jauhar R, Meraj P. Orbital Atherectomy Via Transradial Access: A Multicenter Propensity-Matched Analysis. J Invasive Cardiol. 2019 Nov;31(11):325-330. [PubMed: 31303604]

47.

Doshi R, Shlofmitz E, Patel K, Meraj P. Clinical Outcomes of Atherectomy Prior to Percutaneous Coronary Intervention: A Comparative Assessment of Atherectomy in Patients With Obesity (COAP-PCI Subanalysis). J Invasive Cardiol. 2018 Dec;30(12):465-470. [PubMed: 30318482]

48.

Parikh K, Chandra P, Choksi N, Khanna P, Chambers J. Safety and feasibility of orbital atherectomy for the treatment of calcified coronary lesions: the ORBIT I trial. Catheter Cardiovasc Interv. 2013 Jun 01;81(7):1134-9. [PubMed: 23460596]

49.

Chambers JW, Feldman RL, Himmelstein SI, Bhatheja R, Villa AE, Strickman NE, Shlofmitz RA, Dulas DD, Arab D, Khanna PK, Lee AC, Ghali MG, Shah RR, Davis TP, Kim CY, Tai Z, Patel KC, Puma JA, Makam P, Bertolet BD, Nseir GY. Pivotal trial to evaluate the safety and efficacy of the orbital atherectomy system in treating de novo, severely calcified coronary lesions (ORBIT II). JACC Cardiovasc Interv. 2014 May;7(5):510-8. [PubMed: 24852804]

50.

Megaly M, Sandoval Y, Lillyblad MP, Brilakis ES. Aminophylline for Preventing Bradyarrhythmias During Orbital or Rotational Atherectomy of the Right Coronary Artery. J Invasive Cardiol. 2018 May;30(5):186-189. [PubMed: 29440624]

51.

Lee MS, Nguyen H, Shlofmitz R. Incidence of Bradycardia and Outcomes of Patients Who Underwent Orbital Atherectomy Without a Temporary Pacemaker. J Invasive Cardiol. 2017 Feb;29(2):59-62. [PubMed: 28145873]

52.

Hirai T, Rosenberg J, Nathan S, Blair JEA. Broken arrow: Successful retrieval of a dislodged coronary orbital atherectomy microtip. Catheter Cardiovasc Interv. 2018 Sep 01;92(3):511-514. [PubMed: 30019818]

53.

Tapias LF, Campbell J, Rosenfield K, D'Alessandro DA. Pseudoaneurysm of the left main coronary artery: A complication of orbital atherectomy. Catheter Cardiovasc Interv. 2018 Sep 01;92(3):507-510. [PubMed: 29575766]

54.

Isom N, Masoomi R, Thors A, Bunte M, Prasad A, Hance K, Gupta K. Guidewire fracture during orbital atherectomy for peripheral artery disease: Insights from the Manufacturer and User Facility Device Experience database. Catheter Cardiovasc Interv. 2019 Feb 01;93(2):330-334. [PubMed: 30387234]

55.

Hayashi T, Tanaka Y, Shishido K, Yokota S, Moriyama N, Tobita K, Yamanaka F, Mizuno S, Takahashi S, Saito S. Wire Bias, Insufficient Differential Sanding, and Orbital Atherectomy-Induced Coronary Pseudoaneurysm. Circ Cardiovasc Interv. 2018 Oct;11(10):e007003. [PubMed: 30354637]

56.

Khalid N, Javed H, Rogers T, Hashim H, Shlofmitz E, Chen Y, Khan JM, Musallam A, Torguson R, Bernardo NL, Waksman R. Adverse events and modes of failure related to the FilterWire EZ Embolic Protection System: Lessons learned from an analytic review of the FDA MAUDE database. Catheter Cardiovasc Interv. 2019 Jul 01;94(1):157-164. [PubMed: 30985082]

57.

Doshi R, Shlofmitz E, Meraj P. Utilization and in-hospital outcomes associated with atherectomy in the treatment of peripheral vascular disease: An observational analysis from the National Inpatient Sample. Vascular. 2018 Oct;26(5):464-471. [PubMed: 29466936]

58.

Lee M, Généreux P, Shlofmitz R, Phillipson D, Anose BM, Martinsen BJ, Himmelstein SI, Chambers JW. Orbital atherectomy for treating de novo, severely calcified coronary lesions: 3-year results of the pivotal ORBIT II trial. Cardiovasc Revasc Med. 2017 Jun;18(4):261-264. [PubMed: 28162989]

59.

de Waha S, Allali A, Büttner HJ, Toelg R, Geist V, Neumann FJ, Khattab AA, Richardt G, Abdel-Wahab M. Rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: Two-year clinical outcome of the randomized ROTAXUS trial. Catheter Cardiovasc Interv. 2016 Mar;87(4):691-700. [PubMed: 26525804]

60.

Curtis JP, Schreiner G, Wang Y, Chen J, Spertus JA, Rumsfeld JS, Brindis RG, Krumholz HM. All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients. J Am Coll Cardiol. 2009 Sep 01;54(10):903-7. [PubMed: 19712799]

61.

Khawaja FJ, Shah ND, Lennon RJ, Slusser JP, Alkatib AA, Rihal CS, Gersh BJ, Montori VM, Holmes DR, Bell MR, Curtis JP, Krumholz HM, Ting HH. Factors associated with 30-day readmission rates after percutaneous coronary intervention. Arch Intern Med. 2012 Jan 23;172(2):112-7. [PMC free article: PMC3688066] [PubMed: 22123752]

62.

Naidu SS, Aronow HD, Box LC, Duffy PL, Kolansky DM, Kupfer JM, Latif F, Mulukutla SR, Rao SV, Swaminathan RV, Blankenship JC. SCAI expert consensus statement: 2016 best practices in the cardiac catheterization laboratory: (Endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia intervencionista; Affirmation of value by the Canadian Association of interventional cardiology-Association canadienne de cardiologie d'intervention). Catheter Cardiovasc Interv. 2016 Sep;88(3):407-23. [PubMed: 27137680]

63.

Holmes DR, Rich JB, Zoghbi WA, Mack MJ. The heart team of cardiovascular care. J Am Coll Cardiol. 2013 Mar 05;61(9):903-7. [PubMed: 23449424]

64.

Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. 2012 Feb 28;59(9):857-81. [PubMed: 22296741]

65.

Chu D, Anastacio MM, Mulukutla SR, Lee JS, Smith AJ, Marroquin OC, Sanchez CE, Morell VO, Cook CC, Lico SC, Wei LM, Badhwar V. Safety and efficacy of implementing a multidisciplinary heart team approach for revascularization in patients with complex coronary artery disease: an observational cohort pilot study. JAMA Surg. 2014 Nov;149(11):1109-12. [PubMed: 25207883]

66.

Young MN, Kolte D, Cadigan ME, Laikhter E, Sinclair K, Pomerantsev E, Fifer MA, Sundt TM, Yeh RW, Jaffer FA. Multidisciplinary Heart Team Approach for Complex Coronary Artery Disease: Single Center Clinical Presentation. J Am Heart Assoc. 2020 Apr 21;9(8):e014738. [PMC free article: PMC7428540] [PubMed: 32308096]

Disclosure: Justin Shipman declares no relevant financial relationships with ineligible companies.

Disclosure: Pradyumna Agasthi declares no relevant financial relationships with ineligible companies.